{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107982","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.050828+00:00","generated_at":"2026-05-17T13:53:55.793420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track","bullets":["Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.","Cash and equivalents $104.2M; expected to fund operations into 2026.","Tarcocimab Phase 3 GLOW2 topline data expected Q1 2026; DAYBREAK (wet AMD) topline in Q3 2026.","KSI-101 Phase 1b MESI data: half of patients ≥15 letter gain at Week 12; Phase 3 enrolling.","Investor R&D Day on July 16, 2025 presented 12-week KSI-101 data and commercial strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107982","json":"https://secwatch.observer/filing/0000950170-25-107982.json","markdown":"https://secwatch.observer/filing/0000950170-25-107982.md","text":"https://secwatch.observer/filing/0000950170-25-107982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/0000950170-25-107982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/kod-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:53:55.793420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}